灰区血流储备分数指导下稳定性心绞痛患者PCI与最佳药物治疗比较(COMFORTABLE前瞻性研究):多中心随机对照试验方案
本研究为前瞻性、多中心、开放标签、平行组、随机对照优效性试验,计划纳入410例冠状动脉狭窄且血流储备分数(FFR)处于0.75–0.80灰区的稳定性心绞痛患者,随机分配至药物+经皮冠状动脉介入治疗(PCI)组或单纯药物组,主要终点为1年主要不良心脏事件(MACE)。
要点
- FFR灰区(0.75–0.80)狭窄的血运重建决策尚存争议。
- 研究比较药物+PCI与单纯药物对灰区FFR患者MACE的影响。
- 主要终点为1年MACE,次要终点包括2年和5年MACE。
核心结论
- 旨在验证药物+PCI是否优于单纯药物降低灰区FFR冠状动脉狭窄患者的主要心血管事件。
研究设计与样本
- 前瞻性、多中心、开放标签、平行组、随机对照优效性研究,计划招募410例 eligible 参与者。
关键数值与推荐
- 主要终点为1年MACE,定义为全因死亡、非致死性心肌梗死或非计划靶血管血运重建的复合终点。
- 次要终点包括2年和5年MACE,以及主要终点各组分、心血管死亡、靶血管相关和非靶血管相关MI、所有MI、临床驱动的TVR或非TVR、所有血运重建、支架血栓形成和心绞痛症状状态。
临床怎么用
- 结果将帮助介入心脏病学家对灰区FFR值的冠状动脉狭窄做出血运重建决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Even in the current drug-eluting stent era, revascularization for coronary stenosis with fractional flow reserve (FFR) between 0.75 and 0.80, the so-called "gray zone," is a matter of debate. Previous studies have reported conflicting results regarding outcomes of revascularization versus deferral for coronary stenosis when FFR values are in the gray zone, but these studies have had differing designs and populations. We therefore will investigate whether medical therapy plus percutaneous coronary intervention (PCI) is superior to medical therapy alone in reducing major cardiovascular events in patients presenting with coronary stenosis with gray zone FFR values. METHODS/DESIGN: This is a prospective, multicenter, open-label, parallel group, randomized, controlled, superiority study. A total of 410 eligible participants will be recruited and randomized to either the medical therapy plus PCI group or the medical therapy alone group. The primary endpoint is 1-year major adverse cardiac events (MACEs), defined as a combined endpoint of all-cause death, nonfatal myocardial infarction (MI), or unplanned target vessel revascularization (TVR). Secondary endpoints include MACE at 2 and 5 years. Moreover, each individual component of the primary endpoint, cardiovascular death, target vessel-related and non-target vessel-related MI, all MI, clinically driven TVR or non-TVR, all revascularization, stent thrombosis, and angina symptom status will be evaluated at 1, 2, and 5 years. DISCUSSION: This is the first prospective, multicenter, randomized, controlled study to investigate the superiority of medical therapy plus PCI over medical therapy by itself in reducing major cardiovascular events in patients presenting with coronary stenosis with "gray zone" FFR values. The results will help interventional cardiologists in making revascularization decisions regarding coronary stenosis with gray zone FFR values. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry, UMIN000031526 . Registered on 1 March 2018.
引用
- Kitabata H, Kubo T, Shiono Y, et al. Comparison of clinical outcomes following percutaneous coronary intervention versus optimal medical therapy based on gray-zone fractional flow reserve in stable angina patients with intermediate coronary artery stenosis (COMFORTABLE prospective study): Study protocol for a multicenter randomized controlled trial. Trials. 2019. PMID: 30691507. doi:10.1186/s13063-019-3182-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。